검색
Pharvaris NV
PHVS관심 목록에 추가
33.950USD
-0.630-1.82%
종가 07/01, 16:00（ET）시세는 15분 지연됩니다
2.22B시가총액
손실P/E TTM
자세한 내용은 Pharvaris NV 회사
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Pharvaris NV 정보
종목 코드 PHVS
회사 이름Pharvaris NV
상장일Feb 05, 2021
CEOModig (Berndt B.A.E)
직원 수- -
유형Ordinary Share
회계 연도 종료Feb 05
주소Emmy Noetherweg 2
도시LEIDEN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Netherlands
우편 번호2333 BK
전화31712036410
웹사이트https://pharvaris.com/
종목 코드 PHVS
상장일Feb 05, 2021
CEOModig (Berndt B.A.E)
Pharvaris NV의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
47.61K
-5.61%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
자주 묻는 질문
Pharvaris NV의 상위 5대 주주는 누구인가요?
Pharvaris NV의 상위 5대 주주는 다음과 같습니다: Mr. Berndt Modig, CPA
Pharvaris NV(PHVS)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Pharvaris NV의 주식을 보유한 기관은 총 165곳이며, 이들이 보유한 주식의 총 가치는 약 59.26M로 전체 발행 주식의 90.60%를 차지합니다. 이는 2025Q4 대비 -451327.00 증가한 수치입니다.